PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses

Authors :: Pei He
Keunchil Park
Marcin Kowanetz
Dariusz M. Kowalski
Achim Rittmeyer
Shirish M. Gadgeel
Joachim von Pawel
Fortunato Ciardiello
Joseph W. Leach
Toyoaki Hida
Daniel Waterkamp
Diego Cortinovis
Marcus Ballinger
Jonathan Polikoff
Daniel S. Chen
David R. Gandara
Fabrice Barlesi
Manuel Cobo Dols
C. Matheny
Carlos H. Barrios
Alan Sandler
Source :: Journal of Thoracic Oncology. 12:S9-S10
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Docetaxel
Atezolizumab
030220 oncology & carcinogenesis
Internal medicine
medicine
In patient
business
medicine.drug

Full Text Access

Tools